Gastric inhibitory polypeptide and insulin response to increasing doses of oral glucose: Dependency on glucose amount and volume of the test drink

Schleser, S; Ebert, R.; Creutzfeldt, W.

doi:10.1016/0026-0495(86)90234-9

Cited by 3 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T he glucose response to ^2 doses of glucose has been studied in healthy subjects by several investigators (10,11,(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23). The experiments were most commonly conducted over 2 h. These studies were conducted primarily to determine the best glucose dose to distinguish a healthy subject from a diabetic subject.…”

Section: Discussionmentioning

confidence: 99%

“…In healthy subjects, many studies indicate that insulin response increased with the amount of glucose ingested (10,11,16,(18)(19)(20)23). Several investigators have quantitated insulin-area response to glucose dose; however, the results are not consistent.…”

Section: Gannon and Associatesmentioning

confidence: 99%

“…Christiansen et al (18) reported that the 6-h integrated insulin area increased exponentially with glucose dose. Schleser et al (23) reported that integrated insulin response was linear from 10 to 120 g glucose when glucose was given in a volume of 300 ml, but the response was sigmoidal from 10 to 120 g glucose when glucose was given in a volume of 600 ml. Glucose area increased only 13%, whereas insulin area increased by 69% when the 50-g dose was compared with the 100-g glucose dose.…”

Section: Gannon and Associatesmentioning

confidence: 99%

See 2 more Smart Citations

Effects of Dose of Ingested Glucose on Plasma Metabolite and Hormone Responses in Type II Diabetic Subjects

et al. 1989

View full text Add to dashboard Cite

Ten untreated type II (non-insulin-dependent) diabetic subjects were given 15, 25, 35, and 50 g glucose orally. Plasma glucose, insulin, C-peptide, glucagon, urea nitrogen, alpha-amino acid nitrogen, and lactate concentrations were measured, and net 5-h postprandial areas were calculated. The net glucose-area response to the ingested glucose dose (with the 0-time value as a constant baseline) was best described by a second-order polynomial equation, whereas insulin-area response was best described by a third-order equation. In a separate study, 5 untreated type II diabetic subjects were given only water, and the same metabolites and hormones were measured. Data from this study indicated that the baseline was not constant during the 5 h of study but decreased progressively. The net glucose-area and insulin-area responses to ingested glucose dose (with the decreasing baseline) were then best described by third-order equations. Glucagon, alpha-amino acid nitrogen, and lactate concentrations were exquisitely sensitive to a rise in glucose and insulin concentrations. These were all decreased with the lowest concentration of glucose used. At this dose of glucose, the increase in insulin was only 15 microU/ml.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Gannon and Associatesmentioning

confidence: 99%

Section: Gannon and Associatesmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Dose of Ingested Glucose on Plasma Metabolite and Hormone Responses in Type II Diabetic Subjects

et al. 1989

View full text Add to dashboard Cite

show abstract

Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia

Ebert

Creutzfeldt

1989

Acta diabet. lat

View full text Add to dashboard Cite

The response of immunoreactive gastric inhibitory polypeptide (IR-GIP), immunoreactive insulin (IRI) and immunoreactive C-peptide (IR-C-peptide) to the ingestion of mixed liquid test meals containing 1031 kcal (550 ml) and 422 kcal was studied in 17 obese and 17 normal weight control subjects. When the 422 kcal load was ingested in a volume of 550 ml, the plasma IR-GIP response was significantly greater than in a volume of 225 ml at 15 and 30 min in lean and obese subjects, but the total integrated IR-GIP response was not significantly different between the obese and lean group. Also intraduodenal infusion of 150 ml (280 kcal) of the test meal elicited identical plasma IR-GIP concentrations in lean and obese subjects. An exaggerated IR-GIP response in obese subjects was seen only following the 1031 kcal load (integrated IR-GIP response: 23.6 +/- 1.9 in lean subjects vs 50.3 +/- 3.8 nmol/l/180 min in obese subjects; p less than 0.01). The IRI response was always significantly greater in obese than in lean subjects and not related to the GIP response. Fasting plasma IR-C-peptide levels were significantly elevated in obese subjects (lean: 0.52 +/- 0.04; obese: 1.42 +/- 0.12 nmol/l; p less than 0.005), but the postprandial integrated IR-C-peptide responses in the obese and lean group were identical, indicating decreased hepatic insulin extraction in obesity. It is concluded that an exaggerated IR-GIP response in obesity occurs only after ingestion of a high calorie meal probably as consequence of an increased gastric emptying rate and that the hyperinsulinemic response of obese subjects is not attributable to GIP hypersecretion.

show abstract

Gastric Inhibitory Polypeptide–Dependent Cortisol Hypersecretion — A New Cause of Cushing's Syndrome

Lacroix

Bolté²,

Tremblay³

et al. 1992

N Engl J Med

335

189

View full text Add to dashboard Cite

show abstract

Gastric inhibitory polypeptide and insulin response to increasing doses of oral glucose: Dependency on glucose amount and volume of the test drink

Cited by 3 publications

References 34 publications

Effects of Dose of Ingested Glucose on Plasma Metabolite and Hormone Responses in Type II Diabetic Subjects

Effects of Dose of Ingested Glucose on Plasma Metabolite and Hormone Responses in Type II Diabetic Subjects

Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia

Gastric Inhibitory Polypeptide–Dependent Cortisol Hypersecretion — A New Cause of Cushing's Syndrome

Contact Info

Product

Resources

About